Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

Posted by Brian Himes on Aug 6th, 2026

Revolution Medicines (NASDAQ:RVMD – Get Free Report) issued its earnings results on Wednesday. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02), FiscalAI reports. During the same period last year, the business posted ($1.31) earnings per share.

Here are the key takeaways from Revolution Medicines’ conference call:

Positive Sentiment: Daraxonrasib’s Phase III RASolute 302 results in previously treated metastatic pancreatic cancer showed statistically significant improvements in overall survival, progression-free survival, and quality-of-life measures versus chemotherapy, with a manageable safety profile.
Positive Sentiment: The FDA accepted Revolution Medicines’ NDA for daraxonrasib in pancreatic cancer, while the EMA began an expedited phased review; the company has also established expanded access at sites in nearly all U.S. states and Puerto Rico, providing treatment to more than 2,000 eligible patients.
Positive Sentiment: Early combination data in first-line pancreatic and lung cancer were encouraging, including response rates of 82% for zoldonrasib plus chemotherapy in pancreatic cancer, 82% for zoldonrasib plus standard of care in G12D lung cancer, and 85% for elironrasib plus standard of care in G12C lung cancer.
Positive Sentiment: The company is broadening its registrational pipeline, with Phase III trials underway or planned for multiple pancreatic and lung cancer settings, including RASolute 309, RASolve 307, and RASolve 308; initial Phase III lung cancer data are expected in 2027.
Negative Sentiment: Revolution Medicines raised 2026 GAAP operating expense guidance to $2.1 billion-$2.2 billion as it accelerates manufacturing, clinical development, and commercial preparations; second-quarter net loss widened to $644 million from $248 million a year earlier.

Revolution Medicines Stock Up 0.3%

Shares of NASDAQ RVMD traded up $0.51 during mid-day trading on Thursday, hitting $197.81. The company had a trading volume of 1,744,334 shares, compared to its average volume of 3,141,883. The company has a market capitalization of $42.05 billion, a PE ratio of -27.98 and a beta of 1.39. The business’s 50-day simple moving average is $174.85 and its 200 day simple moving average is $136.44. Revolution Medicines has a 1-year low of $34.00 and a 1-year high of $203.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80.

Insider Activity at Revolution Medicines

In other news, insider Stephen Michael Kelsey sold 4,175 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total transaction of $651,801.00. Following the completion of the transaction, the insider directly owned 291,876 shares of the company’s stock, valued at approximately $45,567,681.12. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 29,600 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $160.12, for a total transaction of $4,739,552.00. Following the completion of the sale, the chief operating officer directly owned 154,647 shares in the company, valued at approximately $24,762,077.64. This trade represents a 16.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 132,497 shares of company stock worth $21,470,486 over the last quarter. 7.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Revolution Medicines

Large investors have recently bought and sold shares of the business. Nextech Invest Ltd. lifted its holdings in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after buying an additional 1,304,347 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Revolution Medicines by 681.8% in the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after acquiring an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Revolution Medicines by 14.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after acquiring an additional 37,345 shares in the last quarter. Invesco Ltd. lifted its stake in Revolution Medicines by 19.3% during the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after purchasing an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC boosted its holdings in Revolution Medicines by 87.9% in the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock valued at $561,000 after purchasing an additional 7,137 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on RVMD. Sanford C. Bernstein began coverage on Revolution Medicines in a research report on Thursday, May 21st. They set a “market perform” rating and a $151.00 price objective on the stock. Truist Financial upped their target price on Revolution Medicines from $179.00 to $210.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Mizuho lifted their price target on Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Evercore reissued an “outperform” rating and set a $230.00 price target on shares of Revolution Medicines in a research report on Thursday. Finally, Royal Bank Of Canada raised their price objective on shares of Revolution Medicines from $182.00 to $203.00 and gave the stock an “outperform” rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines has a consensus rating of “Moderate Buy” and an average target price of $153.05.

Get Our Latest Stock Report on RVMD

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

Positive Sentiment: Needham raised its price target for Revolution Medicines (RVMD) to $240 from $236 and maintained a “Buy” rating, implying approximately 22% upside from the referenced price. The target increase reflects continued confidence in the company’s oncology pipeline and long-term growth potential. Tickerreport analyst rating article
Positive Sentiment: The company continues preparing for a potential launch of daraxonrasib, its lead RAS-targeted cancer therapy. Progress toward a commercial launch could support the stock’s elevated valuation if clinical and regulatory milestones remain on track. Seeking Alpha daraxonrasib preparation article
Neutral Sentiment: Revolution Medicines reported second-quarter 2026 financial results and highlighted continued corporate and pipeline progress. The update gives investors additional visibility into its late-stage oncology programs, but the company remains focused on development rather than generating product revenue. Revolution Medicines second-quarter results release
Negative Sentiment: RVMD posted a second-quarter loss of $3.06 per share, wider than the $2.04 analyst consensus and the $1.31 loss recorded a year earlier. The company also raised its 2026 GAAP operating-expense outlook to approximately $2.1 billion-$2.2 billion, increasing cash-burn concerns and weighing on near-term earnings expectations. Zacks Revolution Medicines earnings article

About Revolution Medicines

(Get Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.